Medscape www.medscape.com

References for:
A Urine Metabolic Ratio of Dextromethorphan and 3-Methoxymorphinan as a Probe for CYP3A Activity and Prediction of Cyclosporine Clearance in Healthy Volunteers

[Pharmacotherapy 19(6):753-759, 1999. © 1999 Pharmacotherapy Publications]

  1. Wrighton SA, Stevens JC. The human hepatic cytochromes P 450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.
  2. Watkins PB. Drug metabolism by cytochrome P450 in the liver and small bowel. Gastroenterol Clin North Am 1992;21:511-26.
  3. Min DI, Perry P, Chen H, Hunsicker LG. Cyclosporine trough levels in predicting allograft rejection and renal toxicity up to 12 months after kidney transplantation. Pharmacotherapy 1998;18(2):282-7.
  4. Kahan BD. Cyclosporine. N Engl J Med 1989;321:1725-38.
  5. Lake KD. Cyclosporine drug interactions: a review. Cardiac Surg State Art Rev 1988;2:617-32.
  6. Lown K, Kolars J, Turgeon K, Merion R, Writhton SA, Watkins PB. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther 1992;51:229-38.
  7. Stein CM, Kinirons MT, Pincus T, Wilkinson GR, Wood AJJ. Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine. Clin Pharmacol Ther 1996;59:47-51.
  8. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-84.
  9. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989;36:89-96.
  10. Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P450 3A probe. I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Ther 1994;271(1):549-56.
  11. Lown K, Thummel KE, Benedict PE, et al. The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther 1995;57:16-24.
  12. Turgeon DK, Leichtman AB, Lown KS, et al. P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients. Clin Pharmacol Ther 1994;56:253-60.
  13. Watkins PB, Hamilton TA, Annesley TM, Ellis CN, Kolars JC, Voorhees JJ. The erythromycin breath test as a predictor of cyclosporine blood levels. Clin Pharmacol Ther 1990;48:120-9.
  14. Turgeon DK, Normolle DP, Leichtman AB, Annesley TM, Smith DE, Watkins PB. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients. Clin Pharmacol Ther 1992;52:471-8.
  15. Krivoruk Y, Kinirons MT, Wood AJJ, Wood M. Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test. Clin Pharmacol Ther 1994;56: 608-14.
  16. Kinirons MT, O'Shea D, Downing TE, et al. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 1993;54:621-9.
  17. Schmid B, Bircher J, Preisig R, Kupfer A. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 1985;38:618-24.
  18. Gonzalez FJ, Skoda RC, Kimura S, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988;331:442-6.
  19. Gorski JC, Jones DR, Wrighton SA, Hall SD. Characterization of dextromethorphan N-demethylation by human liver microsomes. Biochem Pharmacol 1994;48:173-82.
  20. Ducharme J, Abdullah S, Wainer IW. Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chromatogr B 1996;678:113-28.
  21. Jones DR, Gorski C, Hamman MA, Hall SD. Quantification of dextromethorphan and metabolites: a dual phenotypic marker of cytochrome P450 3A4/5 and 2D6 activity. J Chromatogr B 1996;678:105-11.
  22. Jones DR, Gorski JC, Haehner BD, O'Mara EM, Hall SD. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation. Clin Pharmacol Ther 1996;60:374-84.
  23. Chen ZR, Somogyi AA, Bochner F. Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromato-graphy with application to their disposition in man. Ther Drug Monit 1990;12:97-104.
  24. Wang CP, Burckart GJ, Ptachcinski RJ, et al. Cyclosporine metabolite concentrations in the blood of liver, heart, kidney and bone marrow transplant patients. Transplant Proc 1988;20:591-6.
  25. Chan KKH, Wnuck K. Microcomputer based pharmacokinetic programs for calculating absorption rate. Comput Prog Biomed 1983;16:27-34.
  26. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997;62:248-60.
  27. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implication for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995;13(3):129-34.
  28. May DG, Porter J, Wilkinson GR, Branch RA. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population. Clin Pharmacol Ther 1994;55:492-500.
  29. Fardel O, Lecureur V, Guillouzo A. The P-glycoprotein multidrug transporter. Gen Pharmacol 1996;27(8):1283-91.
  30. Sharom FJ. The P-glycoprotein efflux pump: how does it transport drugs? J Membr Biol 1997;160(3):161-75.
  31. von Moltke LL, Greenblatt DJ, Grassi JG, et al. Reevaluation of the specificity of dextromethorphan as an index substrate [abstr]. Clin Pharmacol Ther 1998;63:227.
  32. Gorski JC, Haehner BD, Cutler D, Affrime MB, Hall SD. Lack of correlation between intravenous midazolam and oral dextromethorphan CYP3A phenotypes [abstr]. Clin Pharmacol Ther 1998;63:150.